A Study to Evaluate ALN-2232 in Participants With Obesity
Recruiting · NCT07463846 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- All Parts:
- Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2
- Has a hemoglobin A1c (HbA1c) \<6.5%
Exclusion criteria
- All Parts:
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
- Receiving therapies for chronic weight management or antidiabetic medications
- Note: other protocol defined inclusion/exclusion criteria apply
Where it is running
1 location listed.
- Clinical Trial Site - Mount Royal, Canada